Emerging PSMA Targeted Radioantibody Therapies for Prostate Cancer with CEO, Philip Kantoff, MD

from Rx for Biotech · host Podcast Host Chris Leidli

In this podcast episode, Dr. Philip Kantoff, the CEO, CMO, and Co-Founder of Convergent Therapeutics reviews the company's efforts to develop next-generation radiopharmaceuticals for the treatment of cancer.

Episode metadata supplied by the publisher feed · Published May 9, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Emerging PSMA Targeted Radioantibody Therapies for Prostate Cancer with CEO, Philip Kantoff, MD

0:00 24:44

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Wild WinsDay Wild WinsDay Pump the hump with WILD WINSday 🐪💪: Your 3-minute weekly video boost for leadership, sales, marketing, and business breakthroughs to WIN the day!

Frequently Asked Questions

How long is this episode of Rx for Biotech?

This episode is 24 minutes long.

When was this Rx for Biotech episode published?

This episode was published on May 9, 2023.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!